Abstract
Rare variants in the T-box transcription factor 4 gene (TBX4) have recently been recognised as an emerging cause of paediatric pulmonary hypertension (PH). Their pathophysiology and contribution to persistent pulmonary hypertension in neonates (PPHN) are unknown. We sought to define the spectrum of clinical manifestations and histopathology associated with TBX4 variants in neonates and children with PH.
We assessed clinical data and lung tissue in 19 children with PH, including PPHN, carrying TBX4 rare variants identified by next-generation sequencing and copy number variation arrays.
Variants included six 17q23 deletions encompassing the entire TBX4 locus and neighbouring genes, and 12 likely damaging mutations. 10 infants presented with neonatal hypoxic respiratory failure and PPHN, and were subsequently discharged home. PH was diagnosed later in infancy or childhood. Three children died and two required lung transplantation. Associated anomalies included patent ductus arteriosus, septal defects, foot anomalies and developmental disability, the latter with a higher prevalence in deletion carriers. Histology in seven infants showed abnormal distal lung development and pulmonary hypertensive remodelling.
TBX4 mutations and 17q23 deletions underlie a new form of developmental lung disease manifesting with severe, often biphasic PH at birth and/or later in infancy and childhood, often associated with skeletal anomalies, cardiac defects, neurodevelopmental disability and other anomalies.
Abstract
TBX4 mutations and deletions are associated with abnormal distal lung development, persistent pulmonary hypertension of the newborn, paediatric pulmonary hypertension, multiple congenital anomalies and developmental disabilities http://bit.ly/2UXDrl3
Introduction
Pulmonary arterial hypertension (PAH) is a rare condition in infants and children, with a prevalence ranging between 4.8 and 8.1 cases per million [1–3], that leads to progressive right heart failure and high mortality despite recent progress in diagnosis and treatment [4]. PAH is a precapillary condition, and a subtype of pulmonary hypertension (PH). Although PAH is heterogeneous, genetic defects relevant to pulmonary circulation underlie the majority of familial PAH cases and a significant subset of idiopathic PAH cases. Mutations in the bone morphogenetic protein (BMP) receptor type 2 gene (BMPR2) and other BMP-associated genes are found in ∼70% of familial PAH cases, and 20% of idiopathic PAH cases in adults and children [5–8]. Recent studies have revealed a high prevalence of variants in T-box transcription factor 4 (TBX4), the gene associated with small patella syndrome (SPS) [9], in paediatric PAH [8, 10–12].
In the perinatal period, neonates may present with a form of PH known as persistent pulmonary hypertension of the newborn (PPHN), a condition with different underlying aetiologies causing persistent elevation of pulmonary vascular resistance and failure to transition from a fetal to postnatal circulatory pattern. PPHN is more common than paediatric PAH, with an incidence of 0.18%, 20% of which is seemingly idiopathic [13]. Although PPHN is mostly reversible, with a mortality <10%, a small subset of cases typically unresponsive to therapy have developmental lung diseases [14]. Recently, TBX4 rare variants were described in three neonates with hypoxic respiratory failure caused by developmental lung disease [15, 16], expanding the spectrum of manifestations associated with these gene defects.
Given the potential importance of TBX4 expression during pulmonary development and the association between TBX4 and paediatric PH, we collected data from 19 paediatric patients with identified TBX4 variants and sought to more precisely determine the spectrum of manifestations in infants and children.
Methods
This series consists of cases selected from January 2014 to December 2017 from various clinical centres (supplementary table S1) on the basis of PH initially diagnosed by right heart catheterisation (RHC) in seven cases or echocardiography in 12 cases (table 1) during infancy or childhood and the presence of a TBX4 rare variant identified via clinical or research testing. Small nucleotide variants (SNVs) were identified by next-generation sequencing either from certified clinical laboratories or custom research panels, or by Sanger sequencing (supplementary table S1). For missense variants, the functional impact on protein structure was assessed by PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) and Combined Annotation Dependent Depletion v1.3 (CADD) [17]. Minor allele frequency (<0.05) was checked searching the Exome Aggregation Consortium database [18]. Variants were compared to the ClinVar [19] and ClinGen [20] databases. Copy number variants (CNVs) were determined by chromosomal arrays. Variant significance was determined following the American College of Medical Genetics guidelines for CNVs [21] and SNVs [22]. De-identified patient data, including biometrics, family and neonatal history, initial and subsequent diagnostic studies and functional data, follow-up, and outcome, were extracted from registries or medical records (supplementary table S1). Clinically obtained lung tissue, when available, was re-analysed by a single pathologist (CG). This study was conducted in compliance with local institutional review boards.
Results
Genotype characterisation
18 different heterozygous variants were identified in the 19 patients (including two siblings) which consisted of six CNVs involving the 17q23.2 locus and 12 TBX4 SNVs (table 2). The CNVs comprised two sizes of ~2.2 Mb and ~3.6–3.7 Mb encompassing the whole TBX4 coding sequence plus several other genes (figure 1a). The 2.2 Mb CNV (cases 1, 3, 4 and 5) is a recurrent 17q23.1q23.2 deletion due to segmental duplications that has been previously described [23] and reported in ClinGen. The larger CNV (cases 2 and 6) has only been reported once in ClinVar. The SNVs are novel. Among these, 10 are likely-gene-disrupting variants, including frameshift indel (cases 7–11), premature stop-gain (cases 12–14) and canonical splice site (cases 15 and 16) variants, and three are missense variants affecting the T-box DNA binding domain consensus (cases 17–19) (figure 1b). The two nonsense and two of the frameshift variants located downstream of the T-box domain, in the absence of experimental data demonstrating their gene disrupting effect, were classified as likely pathogenic. The three missense mutations were considered likely pathogenic on the basis of the PolyPhen-2 and/or CADD scores of 0.85–1 and ≥10–20 respectively, conservation of the amino acid position across all vertebrate species, and complete (for p.Gly106 and p.Leu186) or moderate (for p.Val218) conservation in the T-box domain of the 13 human TBX proteins. Of the eight variants in which inheritance was determinable, three (37%) were de novo and five (62%) were familial, with carrier siblings affected with SPS (case 18) or determined to have previously had PAH (cases 13 and 14), and carrier mothers affected with SPS (cases 12 and 15), PAH (case 15) or asymptomatic (case 16). Although the number and nature of tested genes varied from centre to centre (supplementary table S1), no BMPR2, forkhead box F1 (FOXF1) or other PH-related pathogenic gene variants could be found in any tested patient.
Clinical phenotype and outcomes
All patients were born term or late preterm (median 40.0 weeks, interquartile range (IQR) 38.0 weeks), with a female to male ratio of 2.16:1, similar for CNVs and SNVs (tables 1 and 3). Median birthweight was normal for gestational age (median 3075 g, IQR 2450 g), although three neonates were small for gestational age (birthweight z-score<−1.28) [24]. 11 neonates required invasive respiratory support. The most frequent presentation was PPHN in 10 out of 19 neonates (53%), which was severe in eight cases (oxygenation index>25 or need for extracorporeal membrane oxygenation (ECMO)). Four neonates (10%) presented with transient respiratory distress without PH; the remaining five had an uneventful neonatal course. All patients survived their newborn intensive care unit course and were discharged home at a median age of 37 days (range 7–180 days), six with home oxygen and two with sildenafil. In two patients with PPHN history, right ventricular systolic pressures (RVSP) remained elevated after the neonatal period despite therapy and they both died in infancy, at 5 and 8 months. In the remaining eight with PPHN, PH appeared to improve or resolve within the first months of life. Later in childhood, the 17 surviving patients underwent a cardiology evaluation, often for new-onset hypoxaemia or for cardiorespiratory symptoms (table 1). These patients were diagnosed with PH (median age 1.5 years, IQR 0.17 years). The duration of follow-up at the time of this report varied between patients, this study being retrospective (median 10.0 years, IQR 4.7 years). Three patients evolved to end-stage lung disease despite multiple vasodilator therapies: one died at 29 years old and two underwent heart–lung transplantation, one at 11 years and one at 18 years old. 11 patients continue to have chronic PH at their last evaluation, despite the use of multiple PH-targeted therapies in seven patients, a single PH-targeted therapy in one patient, and treatment with supplemental oxygen alone in three patients. PH had resolved at the last follow-up in the remaining three patients (cases 14, 15 and 16: 3 months–10 years), one of whom was medication-free whereas two remained on single vasodilator therapy. 10 out of the 13 patients whose information was retrievable (77%) had skeletal anomalies, including SPS with its typical foot anomaly [9]. Other neurological and developmental disorders included autism, microcephaly, neurosensory deficits and muscular tone anomalies.
Cardiac imaging and haemodynamic analysis
Seven of the patients were assessed by echocardiography alone, while 12 underwent at least one RHC during their treatment course (table 4). 10 patients (53%) had systemic or suprasystemic RVSP in the neonatal period. Eight had patent ductus arteriosus (PDA), which persisted beyond the neonatal period in four patients. Two of these had left-to-right shunting at initial PH diagnosis: one was surgically closed at age 4 years (case 4), and one was haemodynamically insignificant (case 5). Two patients (cases 5 and 11) had right-to-left shunting at the diagnostic RHC persisting at follow-up. An atrial septal defect was present in eight patients (42%). In the 12 patients in whom cardiac catheterisation was performed (median age 1.5 years, IQR 0.17 years), high mean pulmonary artery pressures (mPAP) (60.0 mmHg, IQR 57.5mm Hg) and pulmonary vascular resistance indices (median 16.6 Wood units, IQR 10.7 Wood units) were demonstrated. However, only six out of 12 patients met all criteria for a strict diagnosis of PAH based on American Thoracic Society guidelines [25]. In the six patients with serial RHCs, mPAP and pulmonary vascular resistance indices values were equally elevated or increased at follow-up (data not shown). Among the 10 patients who underwent acute vasoreactivity testing, eight (80%) failed to show a decrease in mPAP of at least 10 mmHg to <40 mmHg [25]. Six had a reduced pulmonary-to-systemic blood flow ratio, indicating significant right-to-left shunts. When performed, pulmonary angiography revealed diffuse anatomical and vascular anomalies, including tortuous pulmonary arterioles, abnormal capillary blush, small pulmonary veins and venules, and pulmonary venous obstruction in one patient (not shown).
Phenotypic characteristics and variant type
Table 3 compares the clinical, functional features between the six CNV and the 13 SNV carriers. Although we observed a greater prevalence of associated cardiac and foot anomalies in CNV carriers, only developmental disability reached statistical significance (100% versus 33%, p=0.029), in line with others' findings [10]. We also observed a trend for greater RHC functional severity in SNV carriers, although this may reflect an older age at first catheterisation in that group. Supplementary table S3, which compares published 17q23 deletions inclusive and exclusive of the TBX2/TBX4 loci including our series, shows a greater prevalence of congenital heart defects (57% versus 0%, p=0.02) and a similar trend for the presence of PH (57% versus 17%, p=0.16) for TBX2/TBX4-inclusive deletions.
Imaging studies
Thoracic images could be only collected in a subset of cases (figure 2, supplementary table S2). Neonatal chest radiography (n=5) showed lung hypoplasia (figure 2a), air leaks and/or ground-glass opacities; chest radiography in infancy and early childhood (n=4) showed a pattern of septal thickening with multifocal areas of dysventilation, bronchial thickening and ground-glass opacities (figure 2b). Computed tomography (CT) scans obtained between 1 and 18 years of age (n=5) showed a spectrum of findings, including multifocal ground-glass opacities, honeycombing and alternating focal cystic changes, and condensed areas and nodules suggesting lobular and lobar fibrosis (figure 2c–f).
Lung histopathology
Pathologic material was available for seven patients, and histological features of lung development and vessel remodelling were analysed semi-quantitatively (table 5). All samples showed diffuse alveolar growth abnormality and variable degrees of pulmonary artery wall remodelling with or without fibrointimal proliferation. No plexiform lesions or vessel necrosis were noted. In patients who had severe symptoms at an early age and underwent biopsy in the neonatal period (cases 1, 7, 12 and 13; figure 3a–i), the histology showed severe disruption of distal lung development characterised by delayed lobular growth with dilated distal airspaces and immature-appearing alveoli without secondary septa, often lined by reactive cuboidal epithelial cells. The distal airspaces appeared enlarged with simplified alveoli. In all cases, there were signs of thickened interstitium; three showed the presence of pale and immature mesenchymal cells as observed in pulmonary interstitial glycogenosis [26], and three had patchy interstitial fibrosis. All had evidence of pulmonary arterial hypertensive remodelling. Back-to-back bronchiolar profiles were seen in two cases and one showed the presence of bronchial vessel recruitment, including intrapulmonary bronchopulmonary anastomoses (IBAs). Overall, these structural changes point to severe disruption of all compartments of distal lung development, reflecting growth arrest during the canalicular or early saccular stage. The lung histology of patients who underwent biopsy in childhood (cases 10a, 18 and 19, and 10b-explant; figure 3j–r) showed evidence of recruited bronchial vascular system, including IBAs and expanded bronchial veins and capillaries, in addition to alveolar simplification and pulmonary artery remodelling. Features of airway remodelling and functional compromise were variably present, characterised by airway wall thickening, increased number of intra-alveolar macrophages and multinucleated giant cells with cholesterol crystals (not shown).
A longitudinal histological analysis was possible in case 10 (biopsy at 2 years and transplant at 18 years). The most striking histological findings included the progression of compromised airway/alveolar growth, characterised by multifocal, markedly underdeveloped and tortuous back-to-back bronchiolar structures, similar to those seen in congenital pulmonary airway malformations [27] or acinar dysplasia (AD) [15]. In addition, pulmonary arteries, lymphatic vessels, airways and pleural vessels showed marked medial wall thickening, and areas of bone formation were noted in the subsequent explant suggesting mesenchymal maldevelopment. Evolving interstitial thickening with fibrosis, IBA recruitment and development of interstitial capillary proliferation were also noted.
Discussion
TBX4 variant carriers are at risk for abnormal distal lung development, PPHN, paediatric-onset PH, multiple congenital anomalies including congenital heart defects and a typical foot malformation, and developmental disabilities. The majority of our patients (63%) presented with a biphasic clinical course consisting of PPHN and neonatal respiratory failure with apparent resolution around 1 month of age, followed by chronic PH later in infancy or early childhood. It is notable that this form of PH fits a precapillary phenotype; however, given the degree of concurrent lung irregularities, these individuals would not technically meet traditional criteria for World Health Organization Classification Group 1 PH (PAH), and might well be classified as Group 3 (PH due to chronic lung disease and/or hypoxia) [6]. Our description of developmental lung disease in patients with TBX4 variants suggests that associated PH may have several causal associations including chronic respiratory disease and hypoxia in addition to idiopathic PH. Given the difficulty of defining these aetiologies in our retrospective series, we are using the term PH (versus PAH) for TBX4-associated vascular disease.
Diffuse developmental lung disorders are rare diseases related to aberrations in primary mechanisms of lung airway and vascular development, and include such diagnoses as AD, congenital alveolar dysplasia and alveolar capillary dysplasia with misalignment of the pulmonary veins (ACDMPV), a lethal neonatal disease associated with FOXF1 variants [28]. Emerging evidence shows that developmental lung disorders are phenotypically heterogeneous. ACDMPV was recently reported in older infants with seemingly precapillary PH, suggesting that FOXF1-related disease has a broader clinical spectrum than initially thought [29, 30]. TBX4 variants were reported in a neonate presenting with lethal AD [15], one with lethal congenital alveolar dysplasia and one with an undefined alveolar growth abnormality and survival beyond 8 months of age [16]. Our pathology findings, with a broader range of age and clinical manifestations, shed light on the pathogenesis of PH in TBX4 mutants, even though we cannot exclude a selection bias because the biopsies were obtained on a clinical basis without unified criteria. This study confirms that various developmental abnormalities affecting alveolar, interstitial and vascular structures underlie TBX4-associated PH. These features imply compromised growth of pulmonary endoderm severely affecting airway/alveolar development, and mesenchymal maldevelopment, reflected by hypertensive remodelling of pulmonary arteries, prominent IBA and other findings of interstitial disease. Our longitudinal observation suggests that these pathological fetal processes continue after birth and progress with age in certain cases, with gradual vascular and lymphatic remodelling and development of the collateral circulation, leading to progressive PH and end-stage lung disease in childhood or young adulthood.
Imaging studies suggest a combination of lung hypoplasia and alveolar dysfunction associated with the neonatal presentation, and progressive bronchial and interstitial changes developing over time in certain cases. The combination of prominent interstitial lung disease and PH in a subset of patients (cases 2, 12, 13, 18 and 19) suggests that mechanisms related to the lung disease, perhaps including chronic hypoxia, may be a contributing factor. However, RHC data suggest severe pulmonary vascular disease in most cases regardless of parenchymal disease, with earlier age at diagnosis and more severe functional values compared to a reference paediatric PAH cohort (the REVEAL cohort [31]). Lack of response to vasoreactivity testing has also been described in children with BMPR2 mutations compared to those without [32], suggesting that genetic forms of PH have distinct vascular pathophysiology.
Kerstjens-Frederikse et al. [10] first described TBX4 mutations in 30% of a cohort of children diagnosed with idiopathic/familial PAH and SPS, as opposed to only 2.5% of a control adult cohort. Zhu et al. [11] calculated a 7.7% prevalence of TBX4-related disease in a larger cohort of paediatric PAH. Levy et al. [12] also estimated a 7.5% TBX4 mutation prevalence in 3 out of 40 infants with PAH. Eyries et al. [8] found a TBX4 variant prevalence of one out of 36 (2.8%) and four out of 168 (2.4%) in French children and adults with PAH, respectively, which was lower than the prevalence of a BMPR2 variant of 19.4% and 14.3%, respectively, in that cohort. A lower frequency of TBX4 variants has been detected in adult-onset PAH than in paediatric-onset PAH, with an overall mutation frequency estimated at 1.5% (25 out of 1633 cases) [8, 10, 11, 33, 34]. Overall, the lack of standardised inclusion and diagnostic criteria among centres in this paediatric series precludes any inference on prevalence or comparison with BMP-related and other PAH genes.
TBX4 variants are associated with multiple anomalies, consistent with disruption of key developmental processes beyond the lung. Not all phenotypic features have the same expressivity. Whereas SPS has a high penetrance, that of PH appears lower [10]. This selective penetrance may putatively depend on the variant itself and its effect on protein dosage and function. However, phenotypical heterogeneity between relatives with a common variant, some having SPS alone and others having a combination of SPS and PH, suggests that TBX4-related PH is not purely monogenic, and that multiple innate and environmental factors may be at play, similarly to what is observed in other genetic forms of PH [6]. In BMPR2-related disease, PAH penetrance is only 20%, and secondary factors modulate expressivity and disease progression [6]. We observed a 2:1 female prevalence, presumably attributable to selective wastage of male fetuses or an abnormal primary sex ratio. Such disparity was observed in adult PH prior to the identification of causative genes [35], and confirmed in large registries [36]. The role of sex-dependent hormonal factors [37] and modifier genes [38] was subsequently demonstrated in BMPR2-related PAH, accounting for female predominance. Putatively, similar mechanisms also exist for TBX4.
The severity of PH does not necessarily correlate with the predicted level of protein expression, as observed in FOXF1-related ACDMPV [39]. Some CNV cases with complete TBX4 haploinsufficiency have less severe PH than others with less gene-disruptive SNVs in our and other series [10], suggesting either a dominant-negative effect or interactions with genetic or environmental factors, which makes genetic-based prognosis challenging.
There was a greater incidence of developmental disability among our patients with CNVs (cases 1–6) than those with SNVs (cases 7–19), suggesting a role for neighbouring genes, although postnatal factors such as PPHN or ECMO cannot be excluded in the CNV group. Comparing our cases with previously published 17q22–q23.2 deletions (supplementary table S3), deletions involving the contiguous TBX2 and TBX4 loci more frequently resulted in PH and congenital heart defects than did those sparing these two genes, suggesting a major role for these two genes in the cardiovascular components of the syndrome, whereas developmental disability had a homogeneous prevalence regardless of TBX2/4 involvement, suggesting again a role for other neighbouring genes.
TBX2 contributes to airway growth and branching [40] and to endocardial cushion formation, critical in the pathogenesis of septal defects [41]. TBX2 missense mutations were identified in individuals with cardiac septal defects, developmental delays and skeletal anomalies, but no PH [42]. We can speculate that, in the complex pathogenesis of congenital heart defect, TBX4 and TBX2 play significant yet distinct roles as causative or modifier genes, with TBX4 contributing to PH onset and severity in this disease group. Conversely, developmental delay, hearing loss and skeletal defects were equally represented independently of TBX2/TBX4 involvement, suggesting multiple gene interactions in the pathogenesis of non-cardiovascular anomalies.
Although TBX4 was initially identified as a critical actor in hind limb development [43], it is highly expressed in developing lung mesenchyme [44], with a highly conserved TBX4 enhancer sequence regulating its spatiotemporal expression [45]. Homozygous TBX4 mutant mouse embryos die at embryonic day 10.5 from defective allantois formation and placental insufficiency [46], and conditional lung mesenchymal TBX4 reduction leads to impaired lung development [44]. TBX4 interacts with fibroblast growth factor 10 (FGF10), an essential regulator of the limb and lung bud growth and airway branching [47], which may account for combined lower limb/pulmonary phenotype in TBX4-associated disease. The FGF10 pathway also regulates epithelial expression of thyroid transcription factor 1 (TTF1, encoded by the NKX2.1 gene), a key factor in alveolar development and surfactant synthesis [48], which may contribute to neonatal respiratory symptoms in TBX4 mutants.
Limitations of this study include a recruitment bias towards paediatric and neonatal forms of TBX4-linked PH; a lack of standardised inclusion criteria that precludes estimating the prevalence of TBX4 variants among infants affected with PPHN, infantile/paediatric PH and congenital heart defects; and variable timing of follow-up precluding outcome comparisons.
In summary, this study confirms that TBX4 variants underlie a complex variety of developmental lung disorders, resulting in a spectrum of clinical manifestations including PPHN, neonatal hypoxic respiratory failure, interstitial lung disease and chronic/progressive paediatric PH, often associated with multisystem anomalies. The variability and complexity of the phenotype and its potential overlap with other PH-associated gene defects warrant thorough molecular genetic testing, involving TBX4-inclusive diagnostic panels combined with CNV microarrays, in order to capture both small and large variants. The biphasic evolution we describe, characterised by hypoxic respiratory failure at birth followed by later-onset PH, suggests that infants with severe PPHN, especially if idiopathic, should undergo an appropriate echocardiography follow-up during infancy and early childhood, and should be tested for TBX4 variants when positive and/or in the presence of suggestive features such as congenital heart defects, foot anomalies and SPS. Larger cohort- and population-based studies are needed to better delineate genotype–phenotype correlations and determine future diagnostic and therapeutic strategies.
Supplementary material
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material ERJ-01965-2018.Supplement
Footnotes
This article has supplementary material available from erj.ersjournals.com
Author contributions: O. Danhaive and S.H. Abman designed the study and supervised the project; O. Danhaive, C. Galambos, E.D. Austin and M.P. Mullen co-wrote the manuscript; C. Galambos performed the pathology studies in collaboration with J. Johnson and R. Boldrini; J.T. Shieh performed the genetic analysis with the contribution of C. Surace, D. Peca, P.B. Agrawal, M.W. Pauciulo and W.C. Nichols; M.P. Mullen and D. Ivy contributed to the cardiology and haemodynamic analysis; E.D. Austin, M.J. Kielt, M. Griese and S.H. Abman contributed to the pulmonology analysis; N. Schwerk, N. Ullmann, R. Cutrera, I. Stucin-Gantar, C. Haass and M. Bansal contributed to clinical data.
Conflict of interest: C. Galambos has nothing to disclose.
Conflict of interest: M.P. Mullen has acted as a site principal investigator on trials sponsored by United Therapeutics, Actelion, Ikaria and GSK, and received travel support from Actelion, outside the submitted work.
Conflict of interest: J.T. Shieh has nothing to disclose.
Conflict of interest: N. Schwerk has nothing to disclose.
Conflict of interest: M.J. Kielt has nothing to disclose.
Conflict of interest: N. Ullmann has nothing to disclose.
Conflict of interest: R. Boldrini has nothing to disclose.
Conflict of interest: I. Stucin-Gantar has nothing to disclose.
Conflict of interest: C. Haass has nothing to disclose.
Conflict of interest: M. Bansal has nothing to disclose.
Conflict of interest: P.B. Agrawal has nothing to disclose.
Conflict of interest: J. Johnson has nothing to disclose.
Conflict of interest: D. Peca has nothing to disclose.
Conflict of interest: C. Surace has nothing to disclose.
Conflict of interest: R. Cutrera has nothing to disclose.
Conflict of interest: M.W. Pauciulo has nothing to disclose.
Conflict of interest: W.C. Nichols has nothing to disclose.
Conflict of interest: M. Griese has nothing to disclose.
Conflict of interest: D. Ivy has contracts (through the University of Colorado School of Medicine) with Actelion, Bayer, Lilly and United Therapeutics for consultancy and research studies.
Conflict of interest: S.H. Abman has nothing to disclose.
Conflict of interest: E.D. Austin has nothing to disclose.
Conflict of interest: O. Danhaive has nothing to disclose.
Support statement: This publication was supported in part by the Frederick and Margaret L. Weyerhaeuser Foundation, the Jayden de Luca Foundation (D. Ivy, C. Galambos), NIH grants R01HL114753 and U01HL121518 (S.H. Abman), NIH/NCATS Colorado CTSA grant number UL1 TR002535, NIH grant HL105333 (W.C. Nichols, M.W. Pauciulo), and an unrestricted grant from the Chiesi Foundation, Parma, Italy (O. Danhaive, R. Cutrera, D. Peca). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received October 17, 2018.
- Accepted April 19, 2019.
- Copyright ©ERS 2019